NL-OMON24009
Recruiting
Not Applicable
A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate CIT-013 in healthy volunteers with and without an intravenous lipopolysaccharide challenge
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Citryll BV
- Enrollment
- 52
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy men or women of non\-child bearing potential (WNCBP), 18 to 55 years of age (inclusive) at screening. The health status is verified by absence of evidence of any clinically significant active or uncontrolled chronic disease following a detailed medical history, a complete physical examination including vital signs, laboratory measurements, and 12\-lead ECG;
- •2\. Signed informed consent, able and willing to comply with the requirements of the study protocol.
- •3\. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and a body weight between 50 and 150 kg, inclusive at screening.
- •4\. All male volunteers must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment.
- •5\. Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.
Exclusion Criteria
- •1\.Any confirmed or suspected disease or condition associated with immune system impairment, including autoimmune diseases, HIV, asplenia or recurrent severe infections.
- •2\.Use of chronic (more than 14 days) immunosuppressant or immunomodulatory drugs within the 3 months prior to IMP administration, or isolated (non\-chronic) use within 30 days prior to IMP administration.
- •3\.Subject has an active, uncontrolled acute or chronic systemic fungal, bacterial, and/or viral, infection within the past 30 days.
- •4\.Subjects with evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases.
- •5\.Subject has a positive SARS\-CoV\-2 PCR based test within 72 hours of receiving CIT\-013\.
- •6\.Use of prescription or over\-the\-counter (OTC) drugs, vitamins, minerals and dietary supplements, within 7 days or 5 half\-lives (whichever is longer) prior to the first dose of study medication until EOS. Herbal supplements
- •7\.and hormone replacement therapy must be discontinued 30 days prior to the first dose of study medication until EOS. Excluded from this list is paracetamol at doses of \<4 g/day on all study days except day 1 of part B.
- •8\.Exceptions will only be made if the rationale is clearly documented by the investigator.
- •9\.Receipt of live or attenuated vaccine 90 days prior to first study intervention administration.
- •10\.Vaccination (completion of 2nd vaccination shot if applicable) against SARS\-CoV\-2 or influenza vaccinations less than 14 days prior to first study drug administration.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics (including food effect), pharmacodynamics and proof of concept of CKD-506 in healthy subjects and inflammatory bowel disease patientsinflammatory bowel diseaserheumatoid arthritis1001796910023213NL-OMON45538Chong Kun Dang Pharmaceutical Corp.80
Completed
Not Applicable
A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to investigate the safety, tolerablility, pharmacokinetics (including food and gender effect), and pharmacodynamics of LNP1955 in healthy subjects.Inflammatory disease conditionsrheumatoid arthritis.10003816NL-OMON42416upin Limited66
Completed
Not Applicable
A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INS-3001 in healthy subjects and patients with moderate aortic valve stenosisNL-OMON52051Vifor (International) Inc.30
Completed
Not Applicable
A first-in-human, randomized, double-blind, placebo-controlled, study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of GLPG4059 in adult, healthy, male subjects.NL-OMON55090Galapagos NV57
Recruiting
Not Applicable
A first-in-human, randomized, double-blind, placebo-controlled study to evaluate, single ascending doses of CIT-013 in healthy volunteers with and without an intravenous lipopolysaccharide challenge and repeat dosing in healthy volunteers and patients with Rheumatoid Arthritis.NL-OMON56333Citryll84